Pakartotinė inkstų navikų krioabliacija ir radijo dažnio abliacija esant vieninteliam inkstui: dviejų klinikinių atvejų aprašymas by Ulys, Albertas et al.
96
ISSN 1392–0995, ISSN 1648–9942 (online)
DOI: http://dx.doi.org/10.15388/LietChirur.2016.1.9957
http://www.chirurgija.lt
L IETUVOS CHIRURGIJA
Lithuanian Surgery
2016, 15 (2–3), p. 96–103
Repeated percutaneous cryoablation and  
radiofrequency ablation for renal tumors  
in a solitary kidney: report of two cases
Pakartotinė inkstų navikų krioabliacija ir radijo dažnio abliacija esant 
vieninteliam inkstui: dviejų klinikinių atvejų aprašymas
Albertas Ulys1, Minija Čerškutė1, Ieva Naruševičiūtė2, Mantas Trakymas2, Arūnas Kulboka1
National Cancer Institute, 1Department of Oncourology, 2Department of Radiology, Santariškių Str. 1, LT-08660 Vilnius, 
Lithuania 
E-mail: minija.cerskute@gmail.com
Nacionalinio vėžio instituto 1Onkourologijos skyrius, 2Radiologijos skyrius, Santariškių g. 1, LT-08660 Vilnius, Lietuva
El. paštas: minija.cerskute@gmail.com
Introduction
Percutaneous cryoablation and radiofrequency ablation are options of minimally invasive treatment while maximizing neph-
ron preservation. It is increasingly used in patients with comorbid conditions, multiple renal cell carcinomas, for patients 
with a single kidney and/or inherited renal cancer syndromes especially in situations when there is a need to preserve renal 
function. The aim of this presentation is to show the benefits (effectiveness and safety) of cryoablation for the patients with 
a solitary kidney from our experience. 
Case reports
We present 2 cases of the patients with a solitary kidney and solid renal masses of <4 cm who underwent percutaneous 
cryoablation and radiofrequency ablation multiple times. A follow up computed tomography was performed at 1 day, 3, 6 
and 12 months and every 6 months thereafter, along with physical examination, urine analysis and serum creatinine. Both 
patients tolerated renal cryoablation and radiofrequency therapy well with no postoperative complications and no change 
in renal function, there was no significant change in serum creatinine from preoperative values. Both patients had complete 
tumor ablation after the treatment. 
Conclusion
Although it is not possible to draw definite conclusions about the safety and efficacy of these techniques from two success-
ful cases, however, these cases demonstrate that these minimally invasive treatment techniques allow kidney cancer to be 
treated with much less disruption of patients’ lives and helps to achieve acceptable oncological results. 
Key words: minimally invasive therapies, renal tumors, interventional radiology
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Įžanga
Perkutaninė inkstų navikų krioabliacija ir radijo dažnio abliacija yra minimaliai invazyvūs gydymo metodai, leidžiantys mak-
simaliai išsaugoti inkstų funkciją. Jie vis dažniau naudojami pacientams, sergantiems sunkiomis gretutinėmis ligomis, esant 
daugybiniams inkstų navikams, pacientams, turintiems tik vieną inkstą ir (ar) turintiems didelį genetinį polinkį susiformuoti 
dauginiams inkstų navikams, ypač tais atvejais, kai labai svarbu išsaugoti inkstų funkciją. Straipsnyje siekta įvertinti šių mini-
maliai invazyvių gydymo metodų naudą (efektyvumą ir saugumą) pacientams, turintiems vienintelį inkstą.
Klinikiniai atvejai
Aprašome ir aptariame du klinikinius atvejus pacientų, kuriems buvo diagnozuoti maži inkstų navikai (<4 cm) vieninteliame 
likusiame inkste ir kurie buvo pakartotinai gydyti krioabliacijos bei radijo dažnio abliacijos metodais Nacionaliniame vėžio 
institute. Kontrolinė kompiuterinė tomografija buvo atlikta kitą dieną po procedūros, po 3, 6 ir 12 mėnesių po procedūros 
ir toliau kas 6 mėnesius, kartu buvo atliekamas fizinis ištyrimas, šlapimo tyrimas ir nustatoma kreatinino koncentracija se-
rume. Abu pacientai inkstų navikų krioabliaciją ir radijo dažnio abliaciją toleravo gerai, pooperacinių komplikacijų, ryškesnių 
inkstų funkcijos pokyčių nebuvo. Serumo kreatinino koncentracija mažai skyrėsi nuo priešoperacinių verčių. Abiem ligoniams 
pasiekta visiška / radikali naviko abliacija po vienos gydymo procedūros. 
Išvada
Nors neįmanoma daryti tikslių galutinių išvadų apie navikų vieninteliame inkste gydymo minimaliai invaziniais metodais 
veiksmingumą ir saugumą tik iš dviejų sėkmingų atvejų, tačiau jie parodo, jog inkstų navikų krioabliacija ir radijo dažnio abli-
acija leidžia minimaliai invazyviu būdu gydyti inkstų navikus ir siekti gerų onkologinių rezultatų.
Reikšminiai žodžiai: minimaliai invazyvi terapija, inkstų navikai, intervencinė radiologija
Introduction
Renal cell carcinoma (RCC) is the most common solid 
tumor of the kidney which accounts for approximately 
90% of all primary renal neoplasms in adults [1]. The 
incidence of RCC is increasing worldwide. In 2012, 
there were approximately 84,400 new cases of RCC 
within the European Union. According to International 
Agency for Research on Cancer, Lithuania is at a second 
place of the list of the 20 countries with the highest rate 
of kidney cancer in 2012 [2]. Due to increasingly used 
cross-sectional imaging techniques, the diagnosis is be-
ing made in an earlier stage. Usually these are small renal 
masses and more than a half of new cases are detected 
incidentally without the typical triad of symptoms: flank 
pain, haematuria and a palpable abdominal mass [3].
Due to the lack of treatment response to chemo-
therapy and radiation therapy, surgery is the treatment 
of choice managing the patients with RCC. Partial 
nephrectomy is considered as a first-line therapy (when-
ever possible) for the patients with a localised tumor less 
than 4 cm in maximum diameter [4]. However, surgi-
cal treatment can be often a cause of consecutive renal 
failure with the need for hemodialysis. Therefore for 
some patients, poor candidates for an open surgery or 
with small peripheral tumors, a less invasive treatment, 
e.g. cryoablation (CRYO), microwave or radiofrequency 
(RF) ablation could be a better choice. Being performed 
using open, laparoscopic and percutaneous approaches 
these nephron-sparing surgery (NSS) techniques are 
widely used among patients with a small renal tumors 
and who have significant co-morbidities or compro-
mised renal function, multiple bilateral kidney tumors, 
inherited renal cancer syndromes or in case of a solitary 
kidney [5]. It offers advantages by reducing periopera-
tive morbidity, decreasing pain and shortening the hos-
pital stay, promoting faster recovery, and importantly 
preserving the renal function [6]. Studies show ablative 
therapies to be promising techniques in managing se-
lected cases of renal cell carcinoma [7] 
Case reports
In the National Cancer Institute during the period from 
2012 to 2014 a total of 10 cryoablation and 81 radiofre-
quency ablation procedures were performed. We present 
two successful clinical cases of the patients with RCC in 
a solitary kidney who underwent multiple percutaneous 
CRYO and RF procedures.
All tumors were imaged on contrast enhanced com-
puted tomography (CT) before percutaneous CRYO or 
RF ablation. Under general anaesthesia combined CT 
and ultrasound guidance was used to place the cryo-
probes into the targeted renal tumor. The total number 
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of probes placed was based on tumor size. CT moni-
toring during the procedure was performed. An argon 
helium based cryoablation system was used with two 
freeze-thaw cycles, at a probe tip temperature of −40°C. 
RF ablation was performed with an RF generator using 
multipolar applicators which were inserted through the 
skin into the kidney tumor using the real-time sonosco-
py. The high frequency alternating current causes tissue 
molecular vibrations. As a result, the temperature exceed 
to 80–100° which resulted in cancer cells destruction. 
The length and number of applicators was chosen by the 
operator on the basis of tumor size and location. 
Both procedures were performed by experienced 
interventional radiologist as an inpatient operation. 
Additionally, a day before the operation titanium mark-
ers were placed around renal tumors. All tumors were 
treated with the intention of providing at least a 0.5 cm 
tumor-free margin.
Both patients were hospitalized from 3 to 9 days 
for observation. Follow-up imaging using contrast 
enhanced CT and physical examination were done at 
the first day after ablation, later at 3–6 months and 
every 6  months afterward. Treatment was considered 
successful when tumors gradually shrunk and showed 
no sign of contrast enhancement, in the treated area on 
follow-up CT.
Renal function was analyzed with serum creatinine 
concentration measured before ablation, on the first 
day after ablation, 3 months after ablation and every 
6 months afterward. 
The 1st patient – 77 year-old man with a clear cell 
RCC metastasis in a solitary right kidney. In 2001 he 
underwent open radical left nephrectomy for the left 
kidney clear cell RCC pT2 G2. In March 2010, he 
began to complain with hemoptysis. Bronchoscopy was 
performed in order to obtain the tissue for biopsy but 
unfortunately acute hemorrhage occurred and it failed 
to get the histological answer. He was admitted to Na-
tional Cancer Institute in June 2010. Contrast enhanced 
CT of the chest revealed a 3cm diameter suspicious as 
a metastatic lesion in the S8 segment of the right lung 
with no evidence of lymphatic nodes invasion. Multidis-
ciplinary team meeting, consisting of urologist, medical 
oncologist, radiation oncologist and thoracic surgeon, 
recommended beginning with the surgical treatment 
because of persisting coughing with blood. Right lower 
lobectomy was performed. Pathological examination of 
the resected tissue revealed a diagnosis of the metastasis 
of clear cell RCC in the right lung. He was followed up 
routinely performing abdominal and chest CT scans.
During the follow up in April 2013 the contrast 
enhanced abdominal CT scan showed two tumors 
of about 1.6 cm diameter at the dorsal surface of the 
middle part of the right kidney. At presentation his 
creatinine level was (92 µmol/l). Titanium markers were 
implanted and percutaneous cryoablation procedure 
was performed (Figure 1). The postoperative creatinine 
level was (98 µmol/l). Biological therapy with sunitinib 
was administrated to the patient at a dose of 50 mg 
orally once daily for 4 weeks, followed by 2 weeks of 
treatment – 2 cycles. 
Figure 1. 1st clinical case. Contrast enhanced CT axial view of 
a solitary right kidney after the 1st cryoablation
Another percutaneous CRYO procedure was per-
formed in March 2014 for the new tumor of a size of 
1.4 cm in the middle part of the right kidney (Figure 2) 
with serum creatinine levels 90 µmol/l before and 
110 µmol/l after the procedure. In June 2015 abdominal 
CT showed two newly onset tumors in the remaining 
kidney. The first was 2.2 cm in maximum diameter in 
the dorsal surface of the lower pole of the kidney and 
another was 1.9 cm in the anterior surface of the upper 
pole of the right kidney. RF was performed with no 
postoperative complications and serum creatinine levels 
were from 99 µmol/l preoperatively and 120 µmol/l 
postoperatively. The last RF ablation was carried out 
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in January 2016 for the tumor of 2 cm, located in the 
dorsal surface of the middle part of the right kidney 
(Figure 3). The postoperative serum creatinine level was 
131 µmol/l.
The patient is currently well and during the last check 
up in May 2016 CT revealed only postoperative changes 
in the right lung and neither local nor distant recurrence 
of the disease was seen. The serum creatinine concentra-
tion during the last visit was 115 µmol/l.
The 2nd patient – 32 year old woman with von 
Hippel-Lindau (vHL) disease. In the history of the 
disease patient became blind with the right eye due to 
the retinal detachment and enucleation of the right eye, 
inserting the prostetic eye was performed. Two surgi-
cal resections of brain stem hemangioblastomas were 
performed. vHL syndrom was diagnosed in 2004. vHL 
molecular examination showed (Santa HOTC): VHL 
c.586A>T (p.L196*). 
In August 2008 underwent a left nephrectomy for the 
left kidney RCC pT2 G2 and right partial nephrectomy 
with adrenelectomy for pT1 G2. In January 2012 the 
right partial nephrectomy was performed repeatedly 
with a histology of RCC pT1a G2. In November 2012 
a CT scanning showed a 1.4 cm x1.7 cm size lesion in 
the lateral surface of the middle part of the right kidney. 
Percutaneous biopsy was obtained from the tumor and 
no specific alterations for vHL disease were noticed on 
histology (Figure  4). Her renal function was normal, 
with serum creatinine 81  µmol/l. Multidisciplinary 
team meeting consisting of urologist, medical oncolo-
gist and radiation oncologist considered percutaneous 
Figure 2. 1st clinical case. Contrast 
enhanced CT before (A – axial view, 
B – sagittal view) and after (C – axial 
view, D – sagittal view) repeated cryo-
ablation of solitary right kidney tumor 
in March 2014
Figure 3. 1st clinical case. Solitary right kidney, new tumor in 
June 2016 (contrast enhanced CT, axial view)
A
B
C
D
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the new tumors (Figure 6). The postablation course in 
the hospital was uneventful with no significant changes 
in serum creatinine levels.
The last abdominal CT was performed in February 
2016 and showed one new tumor in the dorsal surface 
of the middle part of the right kidney of a size of 1.4 
x 1.9 cm. The patient underwent percutaneous radiof-
requency ablation of the right renal mass. 
CRYO as the treatment of choice and the procedure was 
performed (Figure 5). The patient had no immediate 
complications and the postoperative serum creatinine 
was 85 µmol/l.
During the regular check-up in February 2015 five 
new tumors in a solitary right kidney were seen on 
contrast enhanced CT with a size from 1.3 cm to 2.6 cm 
(Figure 5). A percutaneous CRYO was performed for all 
Figure 4. 2nd clinical case. Histological view of right kidney 
tumor percutaneous biopsy
Figure 5. 2nd clinical case. Solitary right kidney tumor (arrow) 
before cryoablation in November 2012 (contrast enhanced CT, 
axial view)
Titanium 
markers
Figure 6. 2nd clinical case. Solitary right kidney tumors (arrows) before cryoablation (A) and after cryoablation (B) in February 2015 
(contrast enhanced CT)
A
B
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After tumor ablation procedures both patients were 
designated for absolute bed rest for minimum 4 hours 
under vital-sign monitoring. Both of them had no 
postoperative complications. Serum creatinine and 
hemoglobin levels were checked the next morning. No 
significant change occurred in the laboratory findings 
and the mean hospital stay was 4,3 days (3–8 days). 
The preprocedure and postprocedure serum creatinine 
levels were recorded and there were only small changes 
in serum creatinine from pretreatment values.
Complete tumor ablation was seen after one treatment 
session. Repeated ablation session was not necessary. 
Contrast enhanced CT after ablation was performed 
and the images were compared with the preablation im-
ages. Immediately following ablation, the ablation zone 
appeared larger than the original tumor but decreased in 
size over time. No contrast enhancement and no enlarge-
ment at the site of ablation was seen.
Discussion
The new accepted standard treatment for small renal 
tumours (<4 cm) is a nephron sparing surgical approach 
technique or image-guided ablative therapy [8]. Radio-
frequency ablation and cryoablation are increasingly 
used in patients with a solitary kidney, because these 
patients are not ideal candidates for surgical resection 
as their renal function must be preserved [9]. 
The management of patients with inherited renal can-
cer syndromes or with multifocal renal tumors is usually 
complicated by the recurrence of the disease, especially 
in those with a solitary kidney. Even if these patients 
are treated with aggressive nephron sparing surgery 
they are still at risk for de novo tumor formation [10]. 
For example, as many as 85% of patients with vHL will 
experience tumor recurrence at 10 years and may need 
multiple surgical interventions [11]. 
The treatment success depends on tumor location 
and size. The ideal renal tumor for the percutaneous 
approach is small (<3 cm), partially exophytic, and 
posteriorly located in a patient who cannot tolerate a 
partial nephrectomy [12]. Relative contraindications 
include younger patient age, larger than 4cm tumors, 
hilar or centrally located tumors, cystic tumors with the 
absolute contraindications of untreatable or irreversible 
coagulopathy or severe medical instability [13]. Usually 
tumors next to or involving the collecting system cannot 
be treated with ablation techniques because of the possi-
bility of either incomplete tumour destruction or injury 
to the collecting system. However, sometimes patients 
who have solitary kidneys and have tumours >4 cm, can 
also be treated in this way to prevent dialysis [14].
Studies have shown, that complications of ablative 
therapies in the treatment of RCCs are usually clinically 
insignificant and that the rate of serious complications 
is very low [15]. Complications may occur as a result of 
injury to the kidney, including it’s vasculature and the 
upper urinary tract collecting system, or injury to the 
surrounding structures. Urologic complications include 
hemorrhage, ureteral stricture, urine leak, and urinary 
tract infection. Non-urologic complications include 
pneumothorax, nerve injury, skin burn, tract seeding 
and other less common medical events [16]. A multi-
institutional review identified complications associated 
with percutaneous and laparoscopic ablative treatment 
of renal tumors. Of these cases 139 were cryoablation 
and 133 were radio frequency ablation. They reported 
a total of 30 complications (11.1%) including 25 mi-
nor (9.2%) and 5 major (1.8%) complications [17]. 
Another prospective review of complications following 
573 renal ablation procedures included 254 RF abla-
tion, 311 cryoablation procedures, and 8 combined 
procedures. The overall complication rate was 11.3% 
(65/573), and the major complication rate was 6.6% 
(38/573). Major complications occurred more com-
monly following cryoablation (7.7%; 24/311) than RF 
ablation (4.7%; 12/254) (p = 0.15) [18].
Literature demonstrate that ablative therapies could 
be an acceptable alternative for the patients with small 
RCCs in a solitary kidney. Mylona SL et al evaluated 
clinical outcomes of the 18 patients with solitary kidney 
and renal cell carcinoma, who underwent percutaneous 
CT-guided radiofrequency ablation with the tumors 
in maximum diameter from 1 to 7 cm. All the tumors 
were treated with totally 24 RF ablation sessions. In 
small (1-3 cm) exophytic tumors technical success was 
85.7%. Residual disease was totally seen in 6/18 tumors 
which required a 2nd RF ablation session. The recur-
rence rate was 11.1%, but no recurrence was noticed 
in tumors less than 3 cm in diameter. No major com-
plications were observed. Serum creatinine values were 
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normal in 17/18 patients and survival ranged from 12 
to 72 months [19]. Another study of 14 patients with 
renal masses in a solitary kidney had been treated with 
percutaneous cryoablation showed no complications 
during treatment. Two patients had gross haematuria 
afterward that resolved within 24 h. The mean follow-
up was 17 (2–30) months, with three patients requiring 
re-treatment for incomplete tumour ablation. There 
was no radiographic evidence of local tumour recur-
rence to date [20].
In retrospective analysis Altunrende F and colleagues 
between the period from April 2002 to March 2010 
evaluated the oncological and functional outcomes of 
computerized tomography guided percutaneous cryo-
therapy and radiofrequency ablation for renal tumors in 
patients with a solitary kidney. Overall 65 patients were 
included 29 (44.6%) underwent cryotherapy and 36 
(55.4%) underwent radiofrequency ablation. Median 
follow-up was 15.1 and 38.8 months. The 3 primary 
treatment failures, including 1 after cryotherapy and 
2 after radiofrequency ablation, were successfully re-
treated with thermal ablation. There were 14 recurrences 
after radio frequency ablation and 3 after cryotherapy. 
Two-year overall survival rates for cryotherapy vs ra-
diofrequency ablation were 89% vs 93%, the cancer 
specific 100% vs 96%, recurrence-free 69% vs 58% and 
metastasis-free survival 86% vs 91%, respectively [21].
As in our presented cases it was important to avoid 
major surgical interventions and to prolong the period 
till radical surgery, especially in the case of the patient 
with vHL disease. The ablative therapies gave the great-
est benefit because they didn’t harm healthy tissue and 
the treatment could be repeated several times. Both RF 
ablation and cryoablation have demonstrated acceptable 
outcomes.
Conclusions
Patients with a history of RCC have higher risk to develop 
another RCC in their remaining kidney. In these two 
demonstrated cases the patients were poor candidates for 
open surgery. And the main goal was to avoid consecu-
tive renal failure with the need for hemodialysis. After 
few ablation therapies no significant change occurred in 
the laboratory finding for both patients and the mean 
hospital stay was short enough. Although it is not possible 
to draw definite conclusions about the safety and efcacy 
of these techniques from two successful cases however, it 
demonstrates that percutaneous ablation technique al-
lows achieve acceptable oncological results. A long-term 
follow-up will be required to confirm these results.
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